Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization

Abstract The authors performed a retrospective and comparative study to compare the efficacy of intravitreal aflibercept and bevacizumab for patients with myopic choroidal neovascularization (mCNV). The patients with treatment-naïve mCNV received 1 + PRN intravitreal bevacizumab from March 2008 to F...

Full description

Bibliographic Details
Main Authors: Jia-Kang Wang, Tzu-Lun Huang, Pei-Yao Chang, Yen-Ting Chen, Chin-Wei Chang, Fang-Ting Chen, Yung-Ray Hsu, Yun-Ju Chen
Format: Article
Language:English
Published: Nature Publishing Group 2018-09-01
Series:Scientific Reports
Subjects:
Intravitreal Aflibercept
Choroidal Neovascularization
Best-corrected Visual Acuity (BCVA)
Mean BCVA
Aflibercept Group
Online Access:https://doi.org/10.1038/s41598-018-32761-z

Internet

https://doi.org/10.1038/s41598-018-32761-z

Similar Items